Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Tuberculosis

Free Subscription Articles published in Am J Respir Crit Care Med Retrieve available abstracts of 36 articles: HTML format

Single Articles

September 2025
1. SOBOL R, Omar SV, Brown T, Joseph L, et al
   Transmission of Bedaquiline-resistant Mycobacterium tuberculosis in KwaZulu-Natal, South Africa.
   Am J Respir Crit Care Med. 2025 Sep 30. doi: 10.1164/rccm.202506-1489.
   PubMed     Abstract available
   
   
   
2. LOADER MI, Vasquez Alves SE, Vasquez Alves NL, Coronel J, et al
   IgE, Matrix Metalloproteinases, and Tuberculosis: Immunologic Consequences of Helminth Co-Infection.
   Am J Respir Crit Care Med. 2025 Sep 23. doi: 10.1164/rccm.202507-1710.
   PubMed    
   
   
   
3. MARTINEZ L, Campbell JI, Linde L, Boulahbal F, et al
   The Effectiveness of Isoniazid Preventive Treatment among Contacts of Multidrug-Resistant Tuberculosis: A Systematic Review and Individual-Participant Meta-Analysis.
   Am J Respir Crit Care Med. 2025 Sep 23. doi: 10.1164/rccm.202411-2340.
   PubMed     Abstract available
   
   
   
4. MENDELSOHN SC, Jackson GT, Wessels E, Beyers E, et al
   Oral Rinse versus Facemask Capture for Non-Sputum Diagnosis of Pulmonary Tuberculosis.
   Am J Respir Crit Care Med. 2025 Sep 12. doi: 10.1164/rccm.202506-1477.
   PubMed    
   
   
   
5. GORDHAN BG, Sewcharran A, Waja Z, Martinson N, et al
   Oral Rinse as an Alternative Diagnostic Specimen for Detection of Tuberculosis.
   Am J Respir Crit Care Med. 2025 Sep 12. doi: 10.1164/rccm.202503-0723.
   PubMed    
   
   
   July 2025
6. TRAUTH J, Laspoulas A, Dakischew O, Gentil K, et al
   Bedaquiline-Pretomanid-Linezolid as a Bridging Therapy for Adverse Events in Drug-Sensitive Tuberculosis.
   Am J Respir Crit Care Med. 2025 Jul 18. doi: 10.1164/rccm.202501-0150.
   PubMed    
   
   
   
7. PHILLIPS PPJ, Peloquin CA, Sterling TR, Kaur P, et al
   Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial.
   Am J Respir Crit Care Med. 2025;211:1277-1287.
   PubMed     Abstract available
   
   
   June 2025
8. SAUKKONEN J, Munsiff S, Winston C, Duarte R, et al
   Reply to Wilson et al.: The 4-Month HPMZ Treatment Regimen for Drug-Susceptible Pulmonary Tuberculosis - A Word of Caution.
   Am J Respir Crit Care Med. 2025.
   PubMed    
   
   
   
9. WILSON JW, Temesgen Z MD, Gaensbauer JG
   The 4-Month HPMZ Treatment Regimen for Drug-Susceptible Pulmonary Tuberculosis - A Word of Caution.
   Am J Respir Crit Care Med. 2025.
   PubMed    
   
   
   
10. MENZIES NA, Marks SM, Hsieh YL, Swartwood NA, et al
    Contribution of Posttuberculosis Sequelae to Life-Years Lost from Tuberculosis Disease in the United States, 2015-2019.
    Am J Respir Crit Care Med. 2025;211:1059-1068.
    PubMed     Abstract available
    
    
    March 2025
11. JANSSEN S, Upton C, de Jager VR, van Niekerk C, et al
    Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and Beyond.
    Am J Respir Crit Care Med. 2025 Mar 21. doi: 10.1164/rccm.202408-1632.
    PubMed     Abstract available
    
    
    January 2025
12. SAUKKONEN JJ, Duarte R, Munsiff SS, Winston CA, et al
    Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2025;211:15-33.
    PubMed     Abstract available
    
    
    December 2024
13. DERENDINGER B, Mochizuki TK, Marcelo D, Shankar D, et al
    C-reactive Protein-based Screening of People with Tuberculosis Symptoms: A Diagnostic Accuracy Study.
    Am J Respir Crit Care Med. 2024 Dec 6. doi: 10.1164/rccm.202405-1000.
    PubMed     Abstract available
    
    
    November 2024
14. 
    Erratum: Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
    Am J Respir Crit Care Med. 2024;210:1280.
    PubMed    
    
    
    August 2024
15. ZAVALA S, Stout JE
    A Balancing Act: Finding the Right Dose of Pyrazinamide to Treat Tuberculosis.
    Am J Respir Crit Care Med. 2024 Aug 22. doi: 10.1164/rccm.202406-1262.
    PubMed    
    
    
    
16. AULD SC, Barczak AK, Bishai W, Coussens AK, et al
    Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the 2(nd) International Post-Tuberculosis Symposium.
    Am J Respir Crit Care Med. 2024 Aug 14. doi: 10.1164/rccm.202402-0374.
    PubMed     Abstract available
    
    
    
17. ROCHE SM, Ottewill C, Mulpeter R, Brown K, et al
    Delayed Tuberculosis Paradoxical Reaction Associated with TNF Inhibitors.
    Am J Respir Crit Care Med. 2024 Aug 12. doi: 10.1164/rccm.202402-0464.
    PubMed    
    
    
    July 2024
18. COHEN T, Colijn C, Warren JL
    Approaches for M. tuberculosis Transmission Inference Based on Genomic Data.
    Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202404-0835.
    PubMed    
    
    
    
19. LEE WC
    Pairs or Paradoxes: Questioning Assumptions in Tuberculosis Transmission Research.
    Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202405-0958.
    PubMed    
    
    
    
20. XU AY, Velasquez GE, Zhang N, Chang VK, et al
    Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial.
    Am J Respir Crit Care Med. 2024 Jul 16. doi: 10.1164/rccm.202401-0165.
    PubMed     Abstract available
    
    
    May 2024
21. DAVIES GR
    Reconsidering the Role of Isoniazid in Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2024 May 1. doi: 10.1164/rccm.202403-0628.
    PubMed    
    
    
    April 2024
22. MATHEMA B, Burzynski J
    One Half of the Pair: Prioritizing Tuberculosis Transmitters for Early Detection.
    Am J Respir Crit Care Med. 2024 Apr 30. doi: 10.1164/rccm.202404-0699.
    PubMed    
    
    
    
23. DRAIN PK
    Another Step Closer to Genomic-informed Therapeutic Dosing for Tuberculosis Drugs.
    Am J Respir Crit Care Med. 2024 Apr 22. doi: 10.1164/rccm.202403-0566.
    PubMed    
    
    
    
24. GAUSI K, Ignatius EH, De Jager V, Upton C, et al
    High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.
    Am J Respir Crit Care Med. 2024 Apr 2. doi: 10.1164/rccm.202311-2004.
    PubMed     Abstract available
    
    
    March 2024
25. VERMA R, Silva KED, Rockwood N, Wasmann RE, et al
    A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
    Am J Respir Crit Care Med. 2024 Mar 5. doi: 10.1164/rccm.202309-1583.
    PubMed     Abstract available
    
    
    February 2024
26. TREVISI L, Brooks MB, Becerra MC, Calderon RI, et al
    Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
    Am J Respir Crit Care Med. 2024 Feb 28. doi: 10.1164/rccm.202307-1217.
    PubMed     Abstract available
    
    
    October 2023
27. ANIDI IU, Kirenga B, Fennelly KP
    Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
    Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1571.
    PubMed    
    
    
    
28. ROCHESTER CL, Alison JA, Carlin B, Holland AE, et al
    Reply to: Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
    Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1714.
    PubMed    
    
    
    July 2023
29. OTTEWILL C, Dolan L, Lopez Bailen E, Roycroft E, et al
    Immunosuppressed Pets as a Conduit for Zoonotic Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jul 25. doi: 10.1164/rccm.202304-0734.
    PubMed    
    
    
    June 2023
30. PATANKAR S, Cruz AT, Douglas-Jones B, Garcia-Prats A, et al
    Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jun 5. doi: 10.1164/rccm.202304-0670.
    PubMed    
    
    
    
31. BRUST JCM
    "Weighting" the Evidence: How Much Bedaquiline Is Enough?
    Am J Respir Crit Care Med. 2023;207:1423-1424.
    PubMed    
    
    
    May 2023
32. MITNICK CD, Nunn AJ
    Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?
    Am J Respir Crit Care Med. 2023;207:1269-1270.
    PubMed    
    
    
    
33. KURBATOVA EV, Phillips PPJ, Dorman SE, Sizemore EE, et al
    A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
    Am J Respir Crit Care Med. 2023;207:1376-1382.
    PubMed     Abstract available
    
    
    April 2023
34. BORGES DE ALMEIDA CP, Mitnick CD
    Intervening on Social Determinants for Better Outcomes in Pediatric Tuberculosis Management.
    Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202303-0601.
    PubMed    
    
    
    
35. MARTINEZ L, Zar HJ
    Reply to: Intervening on Social Determinants for Better Outcomes in Pediatric Tuberculosis Management.
    Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202304-0629.
    PubMed    
    
    
    
36. MASEKELA R, Mandalakas AM
    Pediatric Post-TB Lung Disease: Ready for Prime Time?
    Am J Respir Crit Care Med. 2023;207:975-977.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.